Protara Therapeutics
Clinical-stage biopharma developing TARA-002 cell therapy and IV choline chloride for cancer and rare disease patients
Highlights
- New on EvolcAdded 2026-11-14
About Protara Therapeutics
Protara Therapeutics is a biopharmaceutical company developing therapies for people with cancer and rare diseases. Its lead investigational product, TARA-002, is a cell therapy based on the immunopotentiator OK-432, which is approved in Japan and Taiwan for several oncologic indications and lymphatic malformations.
The company is evaluating TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations in the U.S.; the FDA has granted it Rare Pediatric Disease Designation. Its other investigational product, IV Choline Chloride, is a phospholipid substrate replacement therapy for patients on parenteral support.
Protara was founded on applying modern scientific, regulatory or manufacturing advances to established mechanisms. It is listed on NASDAQ, and its offices are located in the Flatiron District of New York City, where it has open roles in legal, medical affairs and clinical operations.
Product: TARA-002, an investigational OK-432-based cell therapy, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy.
Jobs at Protara Therapeutics
More biotech & pharma companies
Ptcbio
Biopharmaceutical company developing and commercializing medicines for children and adults with serious rare diseasesNew on EvolcRemote-friendlyPulmovant
Developing inhaled therapies for patients with pulmonary diseases, starting with pulmonary hypertension associatedNew on EvolcRatiotx
Develops targeted radiopharmaceuticals for treating cancer, from discovery through early clinical trialsNew on EvolcReCode Therapeutics
Develops mRNA and gene-correction medicines for people with genetically defined diseases, including cystic fibrosisNew on EvolcRecursion
AI-enabled drug discovery and development for pharmaceutical partners and patients with oncology and rare diseasesRemote-friendlySalary transparentRemix Therapeutics
Clinical-stage biotech developing small-molecule mRNA degraders for solid tumors and blood cancersNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Analytics 4High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- MatomoMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content management
- ElementorHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Recruiting
- GreenhouseHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.